文献速递细菌感染、耐药与抗菌药物

医疗保健中β-内酰胺类过敏标签的负担:一项系统综述与荟萃分析

The burden of β-lactam allergy labels in health care: a systematic review and meta-analysis.
PubMed 文献 · Lancet Infect Dis · 2025-03-20

该系统综述与荟萃分析纳入63项研究,评估未经验证的β-内酰胺类过敏标签(BAL)与临床结局的关联。BAL与手术部位感染、耐多药微生物及艰难梭菌感染或定植、住院时间延长及180天或之后死亡相关,但与总体、院内或30天死亡率无关。

要点

  • BAL与手术部位感染风险升高相关(OR 1.60,95%CI 1.27-2.01)。
  • BAL与耐多药微生物感染或定植(OR 1.42)及艰难梭菌感染或定植(OR 1.26)相关。
  • BAL与住院时间延长相关(标准化均数差0.06天),但差异不太可能具有临床意义。

核心结论

  • BAL与一系列不良健康结局相关,尤其是手术部位感染以及耐多药微生物和艰难梭菌感染或定植。
  • 尽管BAL与住院时间延长相关,但观察到的差异不太可能具有临床意义。
  • 纳入研究的异质性和方法学局限可能限制部分结论的稳健性。
  • 这些发现强调需要制定和评估公共卫生举措以遏制不准确的过敏标签,从而减少不必要地避免一线β-内酰胺类抗生素。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Cochrane对照试验中心注册库(CENTRAL)和Embase,时间从2000年1月1日至2024年11月30日。
  • 纳入比较有或无BAL(如任何临床记录中报告或记录)相关临床结局的观察性和干预性研究,不限患者年龄或临床环境。
  • 共纳入63项研究,其中60项(95%)来自高收入国家;研究地点为美洲41项(65%)、欧洲15项(24%)、西太平洋地区7项(11%)。
  • 7项研究为中等质量,无研究被归类为低质量。
  • 采用随机效应模型计算合并估计值,并按地区、国家收入水平、BAL类型、医院环境、样本量、年龄组和证据质量进行亚组分析。

主要发现

  • BAL与手术部位感染率升高相关(OR 1.60,95%CI 1.27-2.01;p<0.0001;I²=70.3%)。
  • BAL与耐多药微生物感染或定植率升高相关(OR 1.42,95%CI 1.22-1.64;p<0.0001;I²=84.4%)。
  • BAL与艰难梭菌感染或定植率升高相关(OR 1.26,95%CI 1.16-1.37;p<0.0001;I²=56.4%)。
  • BAL与住院时间延长相关(标准化均数差0.06天,95%CI 0.05-0.08;p<0.0001;I²=86.1%)。
  • BAL与180天或之后死亡相关,但与总体、院内或30天死亡率无关。

关键数值与推荐

  • BAL与手术部位感染:OR 1.60(95%CI 1.27-2.01),I²=70.3%。
  • BAL与耐多药微生物感染或定植:OR 1.42(95%CI 1.22-1.64),I²=84.4%。
  • BAL与艰难梭菌感染或定植:OR 1.26(95%CI 1.16-1.37),I²=56.4%。
  • BAL与住院时间:标准化均数差0.06天(95%CI 0.05-0.08),I²=86.1%。
  • 除住院时间(p=0.0062)外,大多数结局未检测到显著发表偏倚。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 纳入研究的异质性和方法学局限可能限制部分结论的稳健性。
  • 住院时间结局检测到显著发表偏倚(p=0.0062)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unverified β-lactam allergy labels (BALs) pose a considerable barrier to optimal antimicrobial treatment and represent a growing public health concern. However, no comprehensive meta-analysis has been conducted to explore the associations between BALs and clinical outcomes. We aimed to evaluate existing evidence on the clinical outcomes associated with BALs to determine their global burden. METHODS: In this systematic review and meta-analysis, we searched PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), and Embase from Jan 1, 2000, to Nov 30, 2024. We included observational and interventional studies that compared clinical outcomes related to the presence or absence of a BAL (as reported or documented in any clinical record), irrespective of patient age or clinical setting. The outcomes assessed included the incidence of surgical site infections, the incidence of infections or colonisation due to multidrug-resistant organisms (MDROs) or Clostridioides difficile, mortality, and length of hospital stay. Pooled estimates were calculated using random-effects models, with subgroup analyses conducted by region, country income level, type of BAL, hospital setting, sample size, age group, and quality of evidence. Publication bias was assessed using Begg's funnel plots and Egger's regression test. This study is registered with PROSPERO (CRD42023484030). FINDINGS: 63 studies were included in this systematic review, of which 60 (95%) were from high-income countries. Studies were done in the Americas (41 [65%]), Europe (15 [24%]), and the Western Pacific region (seven [11%]). Seven studies were of moderate quality and none were classified as low quality. No significant publication bias was detected for most outcomes, except for length of hospital stay (p=0·0062). Overall, BALs were associated with increased rates of surgical site infection (OR 1·60, 95% CI 1·27-2·01; p<0·0001; I2=70·3%), rates of infection or colonisation with both MDROs (1·42, 1·22-1·64; p<0·0001; I2=84·4%) and C difficile (1·26, 1·16-1·37; p<0·0001; I2=56·4%), and length of hospital stay (standardised mean difference 0·06 days, 95% CI 0·05-0·08; p<0·0001; I2=86·1%). BALs were also associated with death at or after 180 days but not with overall, in-hospital, or 30-day mortality. INTERPRETATION: BALs are associated with an array of adverse health outcomes, especially surgical site infection and infection or colonisation with MDROs and C difficile. Although BALs were associated with longer hospital stays, the observed difference was unlikely to be clinically relevant. The heterogeneity and methodological limitations of the included studies could limit the robustness of some of our conclusions. However, these findings underscore the need to develop and evaluate public health initiatives to curb inaccurate allergy labelling, thereby reducing unnecessary avoidance of first-line β-lactam antibiotics. FUNDING: National Natural Science Foundation of China.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Fu M, Hu L, Han K, et al. The burden of β-lactam allergy labels in health care: a systematic review and meta-analysis. Lancet Infect Dis. 2025. PMID: 40122092. doi:10.1016/S1473-3099(25)00019-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。